MedTech Dive December 6, 2024
Nick Paul Taylor

The company has generated evidence that shows its system is better than experts at assessing vessel narrowing, plaque volume and composition.

Dive Brief:

  • Cleerly said Wednesday it has raised $106 million to scale the commercialization of a machine learning tool that generates a 3D model of patients’ coronary arteries.
  • The artificial intelligence-driven tool uses coronary computed tomography angiography (CCTA) to noninvasively measure plaque, vessel narrowing and the likelihood of insufficient blood flow.
  • Cleerly has generated evidence that shows its system is better than experts at assessing vessel narrowing, plaque volume and composition, helping it to secure Medicare coverage for the technology.

Dive Insight:

CCTA enables physicians to noninvasively assess the risk of patients with coronary artery disease. The...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Investments, Medical Devices, Technology, Trends
Related Articles:
Only 20% of AI devices for children used pediatric data to train: 3 notes
Medtech firms have cut thousands of jobs this year. Will layoffs continue in 2025?
Proton therapy market in the US projected to reach $2.67 billion by 2033
How Trump’s second term will affect the medtech industry
Cala Health Snags $50M for At-Home Tremor Relief Therapy

Share This Article